Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma	non-small cell lung carcinoma	Not yet recruiting	Phase 2	2026-06-03		NCT07622706

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Peking University Cancer Hospital & Institute	189

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials